The FDA has asked the company to submit its study protocols to the INDs for further discussions in order to provide review and feedback on the proposed studies. Allergy Therapeutics CEO Manuel Llobet said they are …

See the original post:
FDA to lift Allergy Therapeutics INDs clinical hold – Pharmaceutical …